Tandutinib

CAS: 387867-13-2

Ref. TR-T006550

Informação sobre produto

• Nome: Tandutinib
• Sinónimos: 4-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-N-(4-propan-2-yloxyphenyl)piperazine-1-carboxamide, (4-(6-Methoxy-7-(3-piperidylpropoxy)quinazolin-4-yl)piperazinyl)-N-(4-(methylethoxy)phenyl)carboxamide, 1-Piperazinecarboxamide, 4-[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]-N-[4-(1-methylethoxy)phenyl]-, 4-[6-Methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]-N-[4-(1-methylethoxy)phenyl]-1-piperazinecarboxamide, 4-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-N-[4-(1-methylethoxy)phenyl]piperazine-1-carboxamide, Ct 53518, Mln 0518, Mln 518, Tandutinib(TINIBS)
• CAS: 387867-13-2

Descrição

Applications An oral, small-molecule inhibitor of FLT3 for the treatment of AML (acute myelogenous leukemia) and other cancer indications. The drug exhibited limited activity as a single agent in phase I and II clinical trials in patients with AML and myelodysplastic syndrome, but displayed promising antileukemic activity (90% complete remissions) in a phase I/II trial in patients with newly diagnosed AML when administered in combination with cytarabine and daunorubicin.
References Manning, G., et al.: Science, 298, 1912 (2002), Lombardo, L., et al.: J. Med. Chem., 47, 6658 (2004), Knight, Z., et al.: Chem. Biol., 12, 621 (2005), Baselga, J., et al.: Science, 312, 1175 (2006), Garber, K., et al.: Nat. Biotechnol., 24, 127 (2006), Flaherty, K., et al.: Clin. Cancer Res., 13, 747 (2007),

• Marca: TRC

Propriedades químicas

• Peso molecular: 562.70
• Fórmula: C₃₁H₄₂N₆O₄
• Cor/forma: Neat
• InChI: InChI=1S/C31H42N6O4/c1-23(2)41-25-10-8-24(9-11-25)34-31(38)37-17-15-36(16-18-37)30-26-20-28(39-3)29(21-27(26)32-22-33-30)40-19-7-14-35-12-5-4-6-13-35/h8-11,20-23H,4-7,12-19H2,1-3H3,(H,34,38)
• Chave InChI: InChIKey=UXXQOJXBIDBUAC-UHFFFAOYSA-N
• SMILES: COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1